Murphy & Mullick Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
Murphy & Mullick Capital Management's XBI Position: Q3 2026 in Review
Murphy & Mullick Capital Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 176% in Q3 2026, buying an estimated $45.8K and bringing the position to 455 shares worth $71.7K. The position accounts for 0.04% of the portfolio, ranked #249.
Murphy & Mullick Capital Management first reported a position in XBI in Q4 2024 and has held it in 8 quarters since. 962 funds tracked by Wall St. Rank hold XBI as of Q3 2026.
- Murphy & Mullick Capital Management held 455 shares of State Street SPDR S&P Biotech ETF worth $71.7K as of Q3 2026.
- Murphy & Mullick Capital Management bought 290 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $45.8K.
- State Street SPDR S&P Biotech ETF made up 0.04% of Murphy & Mullick Capital Management's portfolio in Q3 2026, its #249 holding.
- Murphy & Mullick Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 8 quarters since.
- 962 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.
Based on Murphy & Mullick Capital Management's 13F filing for Q3 2026, filed 2 Nov 2026.